New findings presented at the American Diabetes Association’s (ADA) 83rd Scientific Sessions reinforce our commitment to providing breakthrough outcomes across the spectrum of care for diabetes and obesity.
LILLY PRESS RELEASES:
|
---|
Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes *Tirzepatide is not approved for the treatment of weight loss. Mounjaro (tirzepatide) is an FDA-approved treatment for adults with type 2 diabetes to improve glycemic control used along with diet and exercise. Mounjaro is not a weight loss drug.
|
ADDITIONAL CONTENT FOR DOWNLOAD OR REFERENCE: